Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection with HIV: clinical case series analysis in North Central Nigeria

Adamu Ishaku Akyala, Chinwe Juliana Iwu

Corresponding author: Chinwe Juliana Iwu, Department of Nursing and Midwifery, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. akyalaisaac@yahoo.com

Received: 09 Jun 2020 - Accepted: 16 Jun 2020 - Published: 10 Sep 2020

Keywords: Coronavirus disease 2019 (COVID-19), transmission, clinical characteristics, viral shedding, HIV and COVID-19 co-infection, Nigeria

Copyright: Adamu Ishaku Akyala et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Adamu Ishaku Akyala et al. Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection with HIV: clinical case series analysis in North Central Nigeria. Pan African Medical Journal. 2020;37(47). 10.11604/pamj.2020.37.47.24200

Available online at: https://www.panafrican-med-journal.com/content/article/37/47/full

Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection with HIV: clinical case series analysis in North Central Nigeria

Adamu Ishaku Akyala¹, Chinwe Juliana Iwu²,*

¹Department of Microbiology, Faculty of Natural and Applied Sciences, Nasarawa State University, Keffi, Nasarawa State, Nigeria, ²Department of Nursing and Midwifery, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

*Corresponding author
Chinwe Juliana Iwu, Department of Nursing and Midwifery, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
Abstract

SARS-CoV-2 has created a global public health emergency with significant mortality and morbidity for people living with HIV (PLWH). Preliminary data reveals persons with immune-compromised status are at risk of developing adverse clinical outcomes from SARS-CoV-2. We aimed to characterise clinical outcomes of HIV patients co-infected with SARS-CoV-2 infection in Nasarawa State, North Central Nigeria. We followed four (4) hospitalised HIV patients that tested positive to SARS-CoV-2 in Nasarawa State and characterised their laboratory findings and clinical outcomes. The consent of the cases was sought and they agreed that their clinical data be published. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) tests for SARS-CoV-2 nucleic acid were performed using nasopharyngeal swabs (novel coronavirus PCR fluorescence diagnostic kit, BioGerm medical biotechnology) at the Nigeria Centre for Disease Control (NCDC) in Abuja, Nigeria. Our study reveals mild clinical outcome among HIV patients with SARS-CoV-2 co-infection. There is need for a syndemic framework to be used to conceptualise SARS-CoV-2 impact among HIV patients and an urgent need to strengthen healthcare programmes within Nigeria.

Introduction

An epidemic of respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China and has spread to other countries of the world [1]. In the past 25 years, several highly transmissible respiratory viruses with epidemic potential have emerged. The most significant pandemics of the 20th century, notably, were influenza viruses in 1918, 1957 and 1968. Since then, several other viral respiratory pathogens have emerged including Middle East respiratory syndrome coronavirus (MERS-CoV), adenovirus-14 and virulent strains of influenza viruses. Soon after the discovery of SARS, new coronaviruses including NL63 and HKU1 were identified [2, 3]. The rapid emergence of these respiratory viruses underscores their epidemic potential and overall threat to global health security. In 2020, a global alert was issued for an emerging yet unknown illness known as severe acute respiratory syndrome (SARS) caused by a novel SARS-CoV-2 [2]. According to the World health Organization (WHO), this novel SARS-CoV-2 virus outbreak has, as of 2:33pm CEST, 29th May 2020, resulted in 5,701,337 confirmed cases and 357,688 deaths, [3] with substantial economic impact. Africa has as at same date, recorded 99,929 cases and 2,427 deaths [3]. The USA Center for Disease and Control (CDC) in March, 2020 revealed that persons living with HIV will be faced with multiple morbidities which might heighten the risk of severe health outcome from the SARS-CoV-2 [4]. Worse clinical outcomes from other associated commodities like; cardiovascular diseases, hypertension, diabetes and other underlying respiratory tract diseases and cancer among others [5]. About 37.9 million people are infected with HIV and AIDS globally [6] and there is paucity of information regarding the impact of SARS-CoV-2 on this population in Nigeria. This study was therefore aimed at understanding clinical outcome of cases of PLHIV who are infected by the in Nasarawa State, North Central Nigeria.

Methods

We performed a case series observational study among SARS-CoV-2 patients who had HIV as an underlying disease between 29th March 2020 to 25th May 2020. Patients who tested positive to SARS-CoV-2 but are not HIV positive were excluded from the study. We collated demographic data, history, hospital admissions and laboratory results such as CD4 count and HIV treatment regimens.

Results

All the four cases were female, sex workers who were intercepted on their way to Nasarawa State
from a high-risk state (province), Kano, Nigeria. They were treated with proteases and integrase inhibitor based antiretroviral therapy (ART), with CD4+ count above 200 cells per μL. We conducted a nasopharyngeal and throat swab for SARS-CoV-2, followed by a RT-PCR assay and the result returned positive. They were admitted after they tested positive in the isolation and treatment center and subsequently were managed for SARS-CoV-2. They had other underlying comorbidities which include: diabetes, chronic sinusitis, pulmonary tuberculosis with accompanying signs and symptoms of COVID-19 including malaise, cough, fever and headaches, and decrease in lymphocyte and white blood cell count. On admission at the two centers in Nasarawa State, their average body temperature, oxygen saturation and respiratory rates were 39°C, 80% and 30 breaths per minute respectively. These cases received norfloxacin 400mg once daily for five days, γ-globulin 400mg/kg once daily for three days and methylprednisolone 0.8mg/kg once daily for three days through intravenous route. The cases are in stable condition and were discharged from the treatment and isolation center. They were asked to self-isolate for two weeks in their homes. Table 1 shows the baseline HIV status, clinical outcomes and demographic characteristics of four cases of novel SARS-CoV-2 co-infection with HIV.

Discussion

Antiretroviral therapy (ART) has been shown to increase the lifespan of people living with HIV and AIDS in sub-Saharan Africa where millions of people are living with HIV. Although clinical complications arising from long-term ART use and aging have been revealed [4, 7], comorbidities such as chronic lung disease, hypertension and diabetes, are associated risk factors within this population. These comorbidities have also been identified as the risk factors for severe SARS-CoV-2 disease [8] which is a cause for concern. On the other hand, severe complications from SARS-CoV-2 might be seen in younger likewise older people living with HIV and AIDS. Such risk is predicated on the fact that PLWH under age 50 are both less likely to be diagnosed (and in effect more likely to be immunocompromised) and also less likely to access and be retained in care, yielding viral suppression of a mere 37% on those age 25-34 [8]. The clinical outcome of patients with HIV and SARS-CoV-2 co-infection in this study suggests that antiretroviral drugs may have protective effects on PLWH as they were stable upon discharge, despite the comorbidities they presented with.

Conclusion

Our study therefore, reveals significant mild clinical outcome among HIV patients with SARS-CoV-2 co-infection. There is need for a syndemic framework to be used to conceptualise SARS-CoV-2 impact among HIV patients and an urgent need to strengthen healthcare programmes within Nigeria. Furthermore, there is need for health system and programme strengthening as SARS-CoV-2 may be an opportunistic infection among PLWH. There is need to have a future contingency plan in addressing HIV-SARS-CoV-2 co-infection by providing structural drivers for disease surveillance. Understanding viral interaction is key in effective treatment of HIV-SARS-CoV-2 co-infection. Worthy of note, antiretroviral treatments in form of pre-exposure prophylaxis (PrEP) or antiretroviral therapy ART for PLWH have some predictive protection against SARS-CoV-2. Our study reveals that HIV-positive patients may not experience significantly worse outcomes in SARS-CoV-2 infection this is because of their antiretroviral regimen which may provide them with some protection.

What is known about this topic

- Antiretroviral therapy (ART) has been shown to increase the lifespan of people living with HIV and AIDS in sub-Saharan Africa where millions of people are living with HIV (PLWH);
Comorbidities such as chronic lung disease, hypertension and diabetes, are associated risk factors among PLWH; Similar comorbidities are also associated with risk of severe outcomes with people infected with SARS-CoV-2.

What this study adds

• The course of COVID-19 in PLWH who are on ART seems to be mild.

Competing interests

The authors declare no competing interests.

Authors' contributions

AIA conceived and designed the study and analysed the data; IA and CJI contributed to writing the manuscript. All the authors have read and agreed to the final manuscript.

Acknowledgments

We thank Dr. Liman Mohammad of the Department of Epidemiology, Nasarawa State Ministry of Health, Lafia for the data. We also acknowledge the Nigeria Center for Disease Control for performing the laboratory test for the novel SARS-CoV-2.

Table

Table 1: baseline HIV status, clinical outcomes and demographic characteristics of novel SARS-CoV-2 co-infection with HIV among cases in Nasarawa State

References

1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224): 565-574. PubMed | Google Scholar
2. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Eurosurveillance. 2020;25(4): 2000058. PubMed | Google Scholar
3. World Health Organization. Coronavirus disease (COVID-19): situation report-130. WHO. 2020.
4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8): 727-733. PubMed | Google Scholar
5. Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The burden of COVID-19 in people living with HIV: a syndemic perspective. AIDS Behav. 2020 Aug;24(8): 2244-2249. PubMed | Google Scholar
6. UNAIDS. UNAIDS data 2019. Joint United Nations Programme on HIV/AIDS, Geneva. 2020.
7. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2): 130-137. PubMed | Google Scholar
8. Giovanetti M, Benvenuto D, Angeletti S, Ciccozzi M. The first two cases of 2019-nCoV in Italy: where they come from. J Med Virol. 2020;92(5): 518-521. PubMed | Google Scholar
Table 1: baseline HIV status, clinical outcomes and demographic characteristics of novel SARS-CoV-2 co-
infection with HIV among cases in Nasarawa State

| Characteristics                      | Case 1 | Case 2 | Case 3 | Case 4 |
|--------------------------------------|--------|--------|--------|--------|
| Age (years)                          | 25     | 30     | 23     | 40     |
| Gender                               | Female | Female | Female | Female |
| Comorbidities                        | Diabetic| Asthmatic| Chronic sinusitis | Tuberculosis |
| HIV-risk factor and exposure         | Sex worker | Sex worker | Sex worker | Sex worker |
| Year of HIV diagnosis                | 2017   | 2010   | 2020   | 2015   |
| Last CD4 cell count (cells per μL)   | 260    | 302    | 251    | 205    |
| Last CD4:CD8 ratio                   | 1.3    | 2.1    | 0.6    | 0.11   |
| HIV viral load at or before admission (copies per mL) | >50 | 600,000 | 12,650 | 30,030 |
| ART-regimen before admission         | Abacavir, lamivudine | Tenofovir, emtricitabine | Alafenamide, tenofovir | Abacavir, lamivudine |
| Symptoms                             | Cough, malaise | Headache | Cough | Malaise, Cough |
| Temperature                          | Fever (36.5°C) | Fever (36.8°C) | Fever (38.9°C) | Fever (39.9°C) |
| Diagnosis                            | Lower respiratory tract infection | Lower respiratory tract infection | Lower respiratory tract infection | Lower respiratory tract infection |
| Duration of onset symptoms (days)    | 3      | 2      | 5      | 4      |
| Laboratory results                   |        |        |        |        |
| Lymphocyte (cells per 10^6/L) F      | 9001   | 7822   | 6232   | 4601   |
| White blood cell count (cells per 10^6/L) | 6420 | 6509 | 7456 | 9801 |
| Severity of infection                | Mild   | Mild   | Mild   | Mild   |